Amr Ahmed
Amr Ahmed is an expert in Pharmacy at Ministry of Health (Saudi Arabia) (Saudi Arabia). As of September 2026, ScienceLeadR ranks Amr Ahmed in the top 1% of experts in Saudi Arabia for Anosmia. Amr Ahmed has authored 56 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 3 of them ongoing. SLR score: 680 (community average: 125). How the SLR is computed.
LeadR Profile
Pharmacy
Subspecialties: Endocrinology - Immunology - Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2021 - 2026
Number : 56
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Commentary: The effects of postponing BCG vaccination on the risk of BCG-related complications among patients with severe combined immunodeficiency disease in Saudi Arabia. PMID 42282960 — vaccines, meningitis, vaccination, severe combined immunodeficiency, tuberculosis, infant | Front Immunol | 2026 | 0 |
| Failure of Hepatic Insulin Clearance via CEACAM1-Mediated Endocytosis: The Missing Physiological Link Between Proinsulin Misfolding, Hyperinsulinemia, and Metabolic Complications in Type 2 Diabetes, Obesity, and NAFLD. PMID 42227093 — diabetes mellitus, protein disulfide-isomerases, proinsulin, insulin resistance, insulin, disulfides, non-alcoholic fatty liver disease, stress, physiological, hyperinsulinism, obesity, tyrosine, endocytosis, diabetes mellitus, type 2 | Probl Endokrinol (Mosk) | 2026 | 0 |
| Sulfur-Dependent Disulfide Bond Disruption in Insulin Resistance: A Hypothesis. PMID 41835053 — insulin resistance, insulin, disulfides | Adv Pharm Bull | 2025 | 0 |
| Glycohypoxia: a hypothesis linking chronic hyperglycemia to functional hypoxia and diabetic complications in type 2 diabetes. PMID 41830794 — diabetes mellitus, hemoglobins, glucose transport proteins, facilitative, growth, niacinamide, nad, nadp, hyperglycemia, adenosine, hypoxia, glucose transporter type 4, diabetes complications, adenine, diabetes mellitus, type 2 | Med Gas Res | 2026 | 0 |
| Localized Semaglutide Injection for Hyperinsulinemia-Induced Lymphatic Dysfunction: A Narrative Review Proposing a Promising Metabolic Perspective for Lymphedema Therapy. PMID 41403736 — injections, cells, tumor necrosis factor-alpha, insulin, lymphangiogenesis, stress, physiological, neoplasms, interleukin-6, hyperinsulinism, therapeutics, lymphedema, semaglutide | Adv Pharm Bull | 2025 | 0 |
Clinical Studies 12
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| SHIELD T1D Shingrix and GLP 1 Agonist for Beta Cell Preservation in Recent Onset Type 1 Diabetes NCT07614412 — diabetes mellitus, cytokines, glucagon-like peptide 1, injections, cells, t-lymphocytes, regulatory, glucagon-like peptide-1 receptor, immunomodulation, insulin, vaccines, insulin-secreting cells, pharmaceutical preparations, cell survival, stress, physiological, sequence homology, insulin secretion, herpes zoster, glycoproteins, autoimmune diseases, diagnosis, hepatitis b e antigens, glucagon, herpes zoster vaccine, injections, intramuscular, apoptosis, t-lymphocytes, injections, subcutaneous, diabetes mellitus, type 1, c-peptide, autoimmunity, semaglutide | Phase 2 | Not yet recruiting | 2027 |
| AIPH TB AI Optimised Pyrazinamide Hydroxychloroquine vs Standard RIPE for Drug Sensitive Pulmonary Tuberculosis A Phase II RCT NCT07467252 — ethambutol, intelligence, tuberculosis, pulmonary, safety, pharmaceutical preparations, drug combinations, duration of therapy, algorithms, tuberculosis, hydroxychloroquine, therapeutics, isoniazid, artificial intelligence, rifampin, pyrazinamide | Phase 2 | Not yet recruiting | 2026 |
| Semaglutide GLP1 Agonists With Degludec Basal bolus Insulin in Early Type 1 Diabetes to Basal bolus NCT06057077 — diabetes mellitus, injections, quality of life, insulin, aged, obesity, therapeutics, diabetes mellitus, type 1, child, semaglutide | Phase 1/Phase 2 | Not yet recruiting | 2024 |
LeadR Networks
Main global connection map